There is hopeful news this week about the survivability of peritoneal mesothelioma, particularly when relapses are treated with a powerful drug called apitolisib.
Peritoneal mesothelioma is a less common form of the rare asbestos-related cancer, malignant mesothelioma. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen.
According to the National Cancer Institute, the one-year survival rates for both peritoneal mesothelioma and the more common pleural mesothelioma is about 40 percent.
But researchers in Surrey, England are reporting two cases of long-term peritoneal mesothelioma survival in women who were treated with apitolisib, a drug that inhibits important cell signaling pathways.
The P13K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) pathways help regulate the cell cycle and are directly related to cell proliferation, cancer, and longevity.
Apitolisib can interrupt these pathways inside cancer cells, making it harder for certain kinds of mesothelioma tumors to grow unchecked.